ADAR1 Capital Management LLC Increases Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

ADAR1 Capital Management LLC grew its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 177.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 196,248 shares of the company’s stock after purchasing an additional 125,446 shares during the period. ADAR1 Capital Management LLC’s holdings in Fulcrum Therapeutics were worth $922,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in FULC. State Street Corp boosted its stake in shares of Fulcrum Therapeutics by 61.4% during the 3rd quarter. State Street Corp now owns 1,680,229 shares of the company’s stock valued at $5,998,000 after buying an additional 638,955 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Fulcrum Therapeutics by 223.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company’s stock valued at $2,032,000 after acquiring an additional 393,202 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Fulcrum Therapeutics by 176.8% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 367,594 shares of the company’s stock worth $1,728,000 after purchasing an additional 234,810 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Fulcrum Therapeutics during the 3rd quarter worth approximately $721,000. Finally, Barclays PLC raised its position in shares of Fulcrum Therapeutics by 367.1% during the 3rd quarter. Barclays PLC now owns 124,141 shares of the company’s stock worth $443,000 after purchasing an additional 97,565 shares during the period. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Trading Down 1.6 %

Fulcrum Therapeutics stock opened at $2.51 on Monday. The company has a market capitalization of $135.49 million, a P/E ratio of -8.10 and a beta of 2.13. Fulcrum Therapeutics, Inc. has a 1-year low of $2.40 and a 1-year high of $10.13. The firm’s fifty day simple moving average is $3.39 and its 200-day simple moving average is $3.67.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). On average, equities research analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Fulcrum Therapeutics has an average rating of “Hold” and a consensus price target of $8.63.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.